Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis

Assistance Publique - Hôpitaux de Paris124 enrolled

Overview

Preliminary report have demonstrated that methotrexate induces an anti bio-medicament tolerization whan administrated just before the first administration of the bio-medicament. Once this tolerization is obtained it seems useless to continue the methotrexate because this treatment has no efficacity in cases of spondyloarthritis.

spondyloarthritis are treated in first intention by NSAIDs but in case of inefficacity biotherapies that inhib the TNF are used. Adalimumab is the most used anti TNF in this indication. Monoclonal antibody uses in therapy is immunogene, and there is a clear link between increase of anti drug antibody and in one hand decrease of drug serum concentration and in an other failure of the therapeutic response. With adalimumab there is an apparition of ADAb in 30%. There are reports suggesting that adding methotrexate to the therapy in a specific timeline allow to prevent the immunization. A previous study shows that association in long terms between methotrexate and adalimumab induce less immunized patients. The investigator's goal is to assess if two methotrexate subcutaneous injections at day 1 and 2 could prevent anti adalimumab antibodies formation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

124

Conditions

Spondyloarthritis

Interventions

MethotrexateDRUG

Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion criteria : * Patients aged from 18 to 90 * Patients suffering from axial SpA, radiographic or non-radiographic according to ASAS criteria (peripheral involvement and/or Inflammatory bowel diseases could be present). * Indication for anti TNF treatment: resistance to at least 2 NSAIDs and no contraindication to adalimumab * No previous treatment with methotrexate in the last 3 months * Stable dosage of steroids (less than 10mg/day of prednisone equivalent) and/or of NSAIDs for at least 10 days * Contraception feminine or masculine * Informed and written consent * Social insurance Exclusion criteria : * Contraindication to methotrexate * Previous treatment with adalimumab * Steroids more than 10mg/day of prednisone equivalent * Previous treatment with: * Etanercept in the last month * Infliximab, golimumab, certolizumab in the last 2 months (Previous treatment hereafter these dates with anti-TNF except adalimumab or secukinumab are not a counterindication) * Current immunosuppressive drugs except methotrexate * Current and proven pregnancy * Project of pregnancy in the next 3 months following inclusion * Legal safeguards * Inclusion in another interventional research project

Locations (17)

Hopital Pellegrin

Bordeaux, France

Hopital Ambroise Paré

Boulogne-Billancourt, France

Hopital La Cavale Blanche

Brest, France

Outcomes

Primary Outcomes

serum concentrations of ADAb anti adalimumab

To assess if 2 subcutaneous injections of methotrexate could prevent anti adalimumab antibodies formation at month 6 in patients with spondyloarthritis

Time frame: 6 month

Secondary Outcomes

residual serum concentration of adalimumab

To compare trough levels of adalimumab at month 1, 3, 6 and 12 in the 2 groups.

Time frame: At 1, 3, 6 and 12 months

serum concentrations of ADAb anti adalimumab

To compare the percentage of immunized patients at month 1, 3 and 12 in the 2 groups

Time frame: At 1, 3 and 12 months

Incidence of Treatment-Emergent Adverse Events

Incidence of Treatment-Emergent Adverse Events as assessed by the number of AE and SAE related to the treatment that occur during the participation of the patient

Time frame: At 1, 3, 6 and 12 months

Comparison of Adalimumab Therapeutic efficacity in term of Activity disease using ASDAS (Ankylosing Spondylitis Disease Activity Score) score.

A therapeutic efficacity will be described as a clinical pertinent change of ASDAS : Ankylosing Spondylitis Disease Activity Score (at least 1,1 point) (a higher score means a worse outcome)

Time frame: At 3, 6 and 12 months

Comparison of Adalimumab Therapeutic efficacity in term of Activity disease using BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) score.

A therapeutic efficacity will be described as a clinical pertinent change of BASDAI : Bath Ankylosing Spondylitis Disease Activity Index (0 to 50 points - a higher score means a worse outcome)

Time frame: At 3, 6 and 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.